

**REMARKS**

Reconsideration of the application is requested in view of the Amendments to the claims and the remarks presented herein.


The claims in the application are claims 1 to 6, 14, 15, 22, 24, all other claims being cancelled.

The only rejection remaining in the application of all the claims under 35 U.S.C. 112, first paragraph with respect to the disorders being treated since the obviousness double patenting rejection was obviated by the terminal disclaimer.

Applicants respectfully traverse this ground of rejection is believed to overcome by limiting the claims to the treatment of pain by combining claims 1 and 25. Therefore, the amendment does not raise new issues after final rejection. The treatment of pain is disclosed in line 25 of page 69 and the pharmacological data on pages 171 to 173. The specification is deemed enabling for the present scope of the claims and withdrawal of this rejection is requested.

In view of the amendments to the claims and the above remarks, it is believed that the claims point out Applicants' patentable contribution. Therefore favorable reconsideration of the application is requested.

Respectfully submitted,  
Hedman and Costigan

  
Charles A. Muserlian #19,683  
Attorney for Applicants  
Tel. 212 302 8989

CAM:mlp  
Enclosures

**CERTIFICATION OF FACSIMILE TRANSMISSION**

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below:

  
Charles A. Muserlian

October 4, 2005